Logo image of TGTX

TG THERAPEUTICS INC (TGTX) Stock Fundamental Analysis

NASDAQ:TGTX - Nasdaq - US88322Q1085 - Common Stock - Currency: USD

36.01  -1.36 (-3.64%)

After market: 36.11 +0.1 (+0.28%)

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to TGTX. TGTX was compared to 557 industry peers in the Biotechnology industry. TGTX has only an average score on both its financial health and profitability. TGTX is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

TGTX had positive earnings in the past year.
TGTX had a negative operating cash flow in the past year.
In multiple years TGTX reported negative net income over the last 5 years.
TGTX had a negative operating cash flow in each of the past 5 years.
TGTX Yearly Net Income VS EBIT VS OCF VS FCFTGTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

The Return On Assets of TGTX (5.96%) is better than 92.84% of its industry peers.
TGTX has a Return On Equity of 16.50%. This is amongst the best in the industry. TGTX outperforms 95.89% of its industry peers.
TGTX has a better Return On Invested Capital (9.52%) than 95.17% of its industry peers.
Industry RankSector Rank
ROA 5.96%
ROE 16.5%
ROIC 9.52%
ROA(3y)-35.91%
ROA(5y)-48.82%
ROE(3y)-121.2%
ROE(5y)-112.84%
ROIC(3y)N/A
ROIC(5y)N/A
TGTX Yearly ROA, ROE, ROICTGTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

TGTX has a Profit Margin of 10.13%. This is amongst the best in the industry. TGTX outperforms 93.20% of its industry peers.
TGTX has a Operating Margin of 15.48%. This is amongst the best in the industry. TGTX outperforms 94.81% of its industry peers.
TGTX has a better Gross Margin (87.43%) than 89.98% of its industry peers.
TGTX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 15.48%
PM (TTM) 10.13%
GM 87.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.04%
GM growth 5YN/A
TGTX Yearly Profit, Operating, Gross MarginsTGTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K

More info and screens

4

2. Health

2.1 Basic Checks

TGTX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for TGTX has been increased compared to 1 year ago.
TGTX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for TGTX is higher compared to a year ago.
TGTX Yearly Shares OutstandingTGTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
TGTX Yearly Total Debt VS Total AssetsTGTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

TGTX has an Altman-Z score of 6.70. This indicates that TGTX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of TGTX (6.70) is better than 82.29% of its industry peers.
A Debt/Equity ratio of 1.03 is on the high side and indicates that TGTX has dependencies on debt financing.
With a Debt to Equity ratio value of 1.03, TGTX is not doing good in the industry: 77.28% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.03
Debt/FCF N/A
Altman-Z 6.7
ROIC/WACC0.6
WACC15.79%
TGTX Yearly LT Debt VS Equity VS FCFTGTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

TGTX has a Current Ratio of 4.02. This indicates that TGTX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of TGTX (4.02) is comparable to the rest of the industry.
A Quick Ratio of 3.04 indicates that TGTX has no problem at all paying its short term obligations.
TGTX's Quick ratio of 3.04 is on the low side compared to the rest of the industry. TGTX is outperformed by 63.15% of its industry peers.
Industry RankSector Rank
Current Ratio 4.02
Quick Ratio 3.04
TGTX Yearly Current Assets VS Current LiabilitesTGTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

8

3. Growth

3.1 Past

TGTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.09%, which is quite good.
The Revenue has grown by 33.54% in the past year. This is a very strong growth!
TGTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 364.59% yearly.
EPS 1Y (TTM)9.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%142.86%
Revenue 1Y (TTM)33.54%
Revenue growth 3Y266.39%
Revenue growth 5Y364.59%
Sales Q2Q%90.4%

3.2 Future

The Earnings Per Share is expected to grow by 98.31% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 38.34% on average over the next years. This is a very strong growth
EPS Next Y523.66%
EPS Next 2Y264.81%
EPS Next 3Y161.7%
EPS Next 5Y98.31%
Revenue Next Year86.16%
Revenue Next 2Y60.48%
Revenue Next 3Y47.96%
Revenue Next 5Y38.34%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
TGTX Yearly Revenue VS EstimatesTGTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
TGTX Yearly EPS VS EstimatesTGTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 150.04, which means the current valuation is very expensive for TGTX.
Based on the Price/Earnings ratio, TGTX is valued cheaper than 90.88% of the companies in the same industry.
TGTX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.32.
With a Price/Forward Earnings ratio of 19.33, TGTX is valued on the expensive side.
Based on the Price/Forward Earnings ratio, TGTX is valued cheaply inside the industry as 92.49% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.13, TGTX is valued at the same level.
Industry RankSector Rank
PE 150.04
Fwd PE 19.33
TGTX Price Earnings VS Forward Price EarningsTGTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, TGTX is valued cheaply inside the industry as 91.23% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 92.56
TGTX Per share dataTGTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
TGTX has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as TGTX's earnings are expected to grow with 161.70% in the coming years.
PEG (NY)0.29
PEG (5Y)N/A
EPS Next 2Y264.81%
EPS Next 3Y161.7%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TGTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TG THERAPEUTICS INC

NASDAQ:TGTX (6/13/2025, 8:00:01 PM)

After market: 36.11 +0.1 (+0.28%)

36.01

-1.36 (-3.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2025-05-05/bmo
Earnings (Next)08-04 2025-08-04
Inst Owners62.82%
Inst Owner Change3.06%
Ins Owners9.7%
Ins Owner Change3.19%
Market Cap5.72B
Analysts80
Price Target43.35 (20.38%)
Short Float %15.74%
Short Ratio8.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.32%
Min EPS beat(2)-83.83%
Max EPS beat(2)77.18%
EPS beat(4)2
Avg EPS beat(4)36.4%
Min EPS beat(4)-83.83%
Max EPS beat(4)185.79%
EPS beat(8)4
Avg EPS beat(8)67.99%
EPS beat(12)7
Avg EPS beat(12)49.15%
EPS beat(16)8
Avg EPS beat(16)35.54%
Revenue beat(2)2
Avg Revenue beat(2)3.08%
Min Revenue beat(2)0.05%
Max Revenue beat(2)6.12%
Revenue beat(4)4
Avg Revenue beat(4)4.03%
Min Revenue beat(4)0.05%
Max Revenue beat(4)9.31%
Revenue beat(8)7
Avg Revenue beat(8)34.64%
Revenue beat(12)9
Avg Revenue beat(12)33.86%
Revenue beat(16)10
Avg Revenue beat(16)19.61%
PT rev (1m)0%
PT rev (3m)5.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.98%
Revenue NQ rev (1m)1.04%
Revenue NQ rev (3m)13.48%
Revenue NY rev (1m)-0.22%
Revenue NY rev (3m)6.38%
Valuation
Industry RankSector Rank
PE 150.04
Fwd PE 19.33
P/S 14.8
P/FCF N/A
P/OCF N/A
P/B 24.09
P/tB 24.09
EV/EBITDA 92.56
EPS(TTM)0.24
EY0.67%
EPS(NY)1.86
Fwd EY5.17%
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.38
OCFYN/A
SpS2.43
BVpS1.49
TBVpS1.49
PEG (NY)0.29
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 5.96%
ROE 16.5%
ROCE 12.05%
ROIC 9.52%
ROICexc 21.46%
ROICexgc 21.46%
OM 15.48%
PM (TTM) 10.13%
GM 87.43%
FCFM N/A
ROA(3y)-35.91%
ROA(5y)-48.82%
ROE(3y)-121.2%
ROE(5y)-112.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.04%
GM growth 5YN/A
F-Score3
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 1.03
Debt/FCF N/A
Debt/EBITDA 4.09
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 2.7
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.02
Quick Ratio 3.04
Altman-Z 6.7
F-Score3
WACC15.79%
ROIC/WACC0.6
Cap/Depr(3y)23.6%
Cap/Depr(5y)87.79%
Cap/Sales(3y)0.17%
Cap/Sales(5y)48.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%142.86%
EPS Next Y523.66%
EPS Next 2Y264.81%
EPS Next 3Y161.7%
EPS Next 5Y98.31%
Revenue 1Y (TTM)33.54%
Revenue growth 3Y266.39%
Revenue growth 5Y364.59%
Sales Q2Q%90.4%
Revenue Next Year86.16%
Revenue Next 2Y60.48%
Revenue Next 3Y47.96%
Revenue Next 5Y38.34%
EBIT growth 1Y23.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year526.5%
EBIT Next 3Y122.83%
EBIT Next 5YN/A
FCF growth 1Y63.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.54%
OCF growth 3YN/A
OCF growth 5YN/A